What SAJA Pharmaceuticals does

SAJA Pharmaceuticals is a Saudi Arabian pharmaceutical manufacturer and regional commercializer headquartered in Jeddah, founded in 1996 as a joint venture between Tamer Group (Saudi Arabia) and the Japanese pharmaceutical majors Astellas Pharma and Daiichi Sankyo. The company manufactures solid dosage forms (tablets, capsules) at a 32,000 sq.m. cGMP-compliant plant in Jeddah, supported by automated visual inspection, serialization and aggregation packaging lines, and a computerized Quality Management System; an additional plant operates in 6th of October City, Egypt (acquired in 2017). Its diversified portfolio spans urology (where it holds GCC market leadership), cardiovascular, diabetes, oncology/specialty, primary care, and nutraceuticals, combining SAJA-developed branded generics with licensed products from global partners including Novartis, Sanofi, Xellia, and Synthon.

SAJA generates revenue through three channels: direct sales of its own branded generics, royalty- and license-based commercialization of partner products across the MENA region, and contract manufacturing / secondary packaging services for international partners. It reaches healthcare providers, hospitals, and pharmacies across 12+ MENA countries (Saudi Arabia, Egypt, UAE, Kuwait, Bahrain, Oman, Jordan, Lebanon, Libya, Sudan, Yemen, Iraq) using a hybrid go-to-market of direct field sales plus a network of in-country agents and distributors, supplemented by medical-association partnerships (e.g., Arab Association of Urology), medical education programs, and university collaborations (Curtin University Dubai). The company has sustained double-digit growth over the last five years and is ranked among the top 25 pharmaceutical companies in the GCC, positioning it as a mid-tier regional manufacturer increasingly aligned with Saudi Vision 2030 localization objectives.

Name

SAJA Pharmaceuticals

Legal name

SAJA Pharmaceuticals Company

Website

https://sajapharma.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SAJA Pharmaceuticals is a Saudi-based JV between Tamer Group, Astellas, and Daiichi Sankyo that manufactures and distributes branded generic and licensed pharmaceuticals across urology, cardiovascular, diabetes, oncology, primary care, and nutraceuticals throughout the MENA region.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Nephrology & Urology Pharmaceuticals (HLAIAAAM)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Branded generic pharmaceuticals
• Pharmaceutical manufacturing
• Licensing and co-commercialization
• Urology therapeutics
• MENA pharmaceutical distribution

Headquarters

HQ city

Jeddah

HQ country

Saudi Arabia

HQ region

Middle East

Offices15 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: SAJA generates revenue through the sale of its diversified portfolio covering urology, cardiovascular, diabetes, oncology, specialty care, primary care, and nutraceuticals. The portfolio includes branded generics, partner products, second brands, and licensed products sold across the MENA region.
2. Licensed and Distributed Products: Revenue from licensed products from international partners (Astellas, Daiichi Sankyo, Novartis, Sanofi, Synthon, Xellia) commercialized in the MENA region, including technology transfer and co-development arrangements.
3. Contract Manufacturing / Secondary Packaging: SAJA provides secondary packaging services at its manufacturing facility, reflecting trust in the high quality of SAJA's facilities from international partners, generating revenue from toll manufacturing arrangements.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

SAJA Pharmaceuticals manufactures and distributes a diversified portfolio of branded generic and licensed pharmaceutical products in solid dosage forms (tablets, capsules, transdermal patches) across urology, cardiovascular, diabetes, oncology/specialty, primary care, and nutraceuticals. The company operates cGMP-compliant manufacturing facilities in Saudi Arabia and Egypt, and serves healthcare providers, hospitals, and pharmacies across the MENA region through its own commercial organization and a network of regional agents. It also provides licensing, co-commercialization, and secondary packaging services to international pharmaceutical partners.

Product overview

SAJA Pharmaceuticals is a regional pharmaceutical company offering a diversified portfolio of branded generic and licensed pharmaceutical products across six therapeutic categories: Urology, Cardiovascular, Diabetes, Specialty, Primary Care, and Nutraceuticals. The company operates as a joint venture between Tamer Industries (Saudi Arabia) and two Japanese pharmaceutical companies (Daiichi Sankyo and Astellas Pharma). SAJA manufactures solid dosage forms (tablets and capsules) at its facility in Jeddah, Saudi Arabia, and distributes products throughout the MENA region. The product portfolio includes established brands across multiple therapy areas, with licensed products from global pharmaceutical partners including Astellas, Daiichi Sankyo, Novartis, Sanofi, Xellia, and Synthon. The company is expanding into specialty/niche areas including critical care, hospital products, and biotechnology-based treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Alamax Alamax is a film-coated tablet containing Alpha Lipoic Acid 600mg, an antioxidant supplement for oral use, positioned in SAJA's nutraceuticals portfolio.
• Lactoglobin Lactoglobin is a 100mg Lactoferrin capsule for oral use, a food supplement derived from cow milk, positioned in SAJA's nutraceuticals portfolio.
• Allair 4 & 5 mg Allair is a Montelukast Sodium chewable tablet in 4mg and 5mg strengths for treatment of allergic rhinitis and asthma prevention in children aged 2-14 years.
• Allair 10 mg Allair 10mg is a Montelukast Sodium chewable tablet for treatment of adults and adolescents 15 years and older with allergic conditions and exercise-induced bronchoconstriction.
• D-CURA D-CURA is a Cholecalciferol 25,000 IU ampoule for oral use, a vitamin D3 supplement for prevention and treatment of vitamin D deficiency.
• Itrazol Itrazol is an Itraconazole 100mg capsule for oral use, an antifungal medication for treatment of vulvovaginal candidosis, pityriasis versicolor, dermatophytoses, oral candidosis, fungal keratitis, systemic mycoses, and onychomycosis.
• Levaquin Levaquin is a Levofloxacin 500mg film-coated tablet for treatment of bacterial infections in sinuses, lungs, urinary tract, prostate gland, and skin.
• Moxican Moxican is a Moxifloxacin 400mg film-coated tablet for treatment of bacterial infections including sinus infections, respiratory infections, and pelvic inflammatory disease.
• Pantomax Pantomax is a Pantoprazole 20mg and 40mg tablet for treatment of duodenal ulcers, gastric ulcers, reflux esophagitis, and conditions requiring acid suppression.
• Roxonin Roxonin is a Loxoprofen Sodium 60mg tablet for relief of inflammation and pain in rheumatoid arthritis, osteoarthritis, lower back pain, and post-operative pain.
• Roxonin Tape Roxonin Tape is a Loxoprofen Sodium 50mg and 100mg transdermal patch for relief of acute and chronic inflammation and pain through topical NSAID administration.
• Depojoy Depojoy is a Dapoxetine 30mg and 60mg film-coated tablet for treatment of premature ejaculation in adult men aged 18-64 years.
• Tando Tando is a Tadalafil 5mg and 20mg film-coated tablet for treatment of erectile dysfunction in adult men.
• Levozin Levozin is a Levocetirizine dihydrochloride 5mg film-coated tablet for treatment of allergic rhinitis and urticaria symptoms.
• Olmetec Olmetec is an Olmesartan Medoxomil 20mg and 40mg tablet for treatment of essential hypertension.
• Olmetec Plus Olmetec Plus is a combination tablet of Olmesartan Medoxomil with Hydrochlorothiazide (20mg/12.5mg, 40mg/12.5mg, 40mg/25mg) for treatment of hypertension.
• SEVIKAR SEVIKAR is a combination tablet of Olmesartan Medoxomil and Amlodipine Besilate (20mg/5mg, 20mg/10mg, 40mg/5mg, 40mg/10mg) for treatment of hypertension.
• SEVIKAR HCT SEVIKAR HCT is a triple combination tablet of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in various strengths for treatment of hypertension.
• Arbavasc HCT Arbavasc HCT is a triple combination tablet of Valsartan, Amlodipine, and Hydrochlorothiazide for treatment of hypertension in patients requiring multiple antihypertensive agents.
• Arbaval Arbaval is a Valsartan 40mg, 80mg, 160mg, and 320mg film-coated tablet for treatment of hypertension and heart failure.
• Arbaval Plus Arbaval Plus is a combination tablet of Valsartan with Hydrochlorothiazide (160/12.5mg, 160/25mg, 320/25mg) for treatment of hypertension.
• Ezechol Ezechol is an Ezetimibe 10mg tablet for lowering cholesterol levels by inhibiting intestinal absorption of cholesterol.
• Lixiana Lixiana is an Edoxaban 15mg, 30mg, and 60mg film-coated tablet for prevention of blood clots in atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism.
• Rozavi Rozavi is a Rosuvastatin 10mg and 20mg film-coated tablet for treatment of hypercholesterolemia and cardiovascular risk reduction.
• Simvaten Simvaten is a Simvastatin 10mg, 20mg, and 40mg tablet for treatment of hypercholesterolemia and cardiovascular disease prevention.
• Jalra Jalra is a Vildagliptin 50mg tablet for treatment of type 2 diabetes as monotherapy or in combination with other antidiabetic agents.
• Jalra M Jalra M is a combination tablet of Vildagliptin and Metformin (50mg/850mg, 50mg/1000mg) for treatment of type 2 diabetes.
• Vivaro Vivaro is an Insulin Glargine solution for injection in pre-filled pens for treatment of diabetes mellitus in adults, adolescents, and children 6 years and older.
• Fegona Fegona is a Fingolimod 0.5mg capsule for treatment of relapsing-remitting multiple sclerosis in adults.
• Envica Envica is an Entecavir 0.5mg and 1mg tablet for treatment of chronic hepatitis B virus infection in adults.
• XEMETAN XEMETAN is an Exemestane 25mg sugar-coated tablet for treatment of hormone-dependent breast cancer in postmenopausal women.
• Marlet Marlet is a Letrozole 2.5mg film-coated tablet for treatment of breast cancer in postmenopausal women.
• Mavec Mavec is an Imatinib 100mg and 400mg film-coated tablet for treatment of chronic myeloid leukemia, Philadelphia chromosome-positive ALL, GIST, and other malignancies.
• Lidova Lidova is a Lenalidomide 5mg, 10mg, and 25mg hard capsule for treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.
• Bonteo Bonteo is a Teriparatide (rDNA) 20 micrograms/80 microliters solution for injection in pre-filled pen for treatment of osteoporosis.
• Vesicare Vesicare is a Solifenacin Succinate 5mg and 10mg tablet for symptomatic treatment of urge incontinence and overactive bladder syndrome.
• Betmiga Betmiga is a Mirabegron 50mg tablet for treatment of symptoms of overactive bladder including urgency, frequency, and urgency incontinence.
• OMNIC OCAS OMNIC OCAS is a Tamsulosin Hydrochloride 0.4mg prolonged-release tablet for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
• Critical Care Product Line (Xellia) Critical care product line of anti-infective treatments for hospital patients with serious and life-threatening infections, developed in partnership with Xellia Pharmaceuticals.
• Contract Manufacturing (Secondary Packaging Services) SAJA provides secondary packaging services at its manufacturing facility, including a dedicated secondary packaging localization area to help international partners begin localization, supported by serialization and aggregation for regulatory compliance and supply chain traceability.
• Pharmacovigilance and Drug Safety Services SAJA operates pharmacovigilance and drug safety services, including an Adverse Event Reporting service, to support regulatory compliance and patient safety across its product portfolio.

Quantifiable outcome

• GCC region Market Leader in Urology
• +3 more outcomes

Named customers1 record

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core, major and minor.

• LIFEPharmacoreStrategic or Co-development Partner · 1 January 2025SAJA Pharma signed a Memorandum of Understanding (MOU) with LIFEPharma to form a powerful strategic collaboration combining SAJA's strong commercial presence and diverse portfolio (urology, cardiovascular, diabetes, oncology, specialty care, primary care) with LIFEPharma's robust manufacturing capabilities including a Dubai-based facility and being the only US FDA-approved pharmaceutical manufacturer in the UAE. The partnership aims to strengthen regional pharmaceutical manufacturing and supply chain capabilities and expand access to high-quality affordable treatments.
• SynthoncoreStrategic or Co-development Partner · 1 December 2022SAJA entered into a partnership with Synthon (global leader in complex generic pharmaceuticals) to commercialize several products in the MENA region. The partnership combines Synthon's high-quality products with SAJA's local industry-leading expertise to accelerate access to high-quality and affordable medicines. This unique partnership advances Synthon's strategy of strengthening commercial presence in the MENA region.
• Curtin University DubaimajorStrategic or Co-development Partner · 1 November 2022SAJA Pharma signed an MoU with Curtin University Dubai (ranked in the top 1% of universities worldwide) to formalize cooperation through training programs, internship and placement for students, and exchange of knowledge and research opportunities. The signing coincided with the 25th jubilee celebration of SAJA Pharma and the centennial celebration of Tamer Group. Mahmoud Ghaly, General Manager – SAJA GCC & Yemen Cluster, stated SAJA aims to enhance knowledge and skills of the medical community.
• Arab Association of Urology (AAU)majorStrategic or Co-development Partner · 1 June 2022The Arab Association of Urology (AAU), the largest urological association in the Middle East, signed an MoU with SAJA to promote effective scientific and training programs to improve urology practice through the Arab School of Urology (ASU) education platform. SAJA and AAU pledged to promote public awareness programs for preventable urological health issues including urinary incontinence, overactive bladder (OAB), and benign prostatic hyperplasia (BPH). Dr. Mohammed Khalil, CEO of SAJA, and Dr. Yasser Farahat, Secretary-General of AAU, signed the MoU.
• Xellia PharmaceuticalscoreStrategic or Co-development Partner · 1 October 2020SAJA entered into a strategic collaboration with Xellia Pharmaceuticals to launch its first Critical care brands that serve a wide range of infectious diseases. Xellia is a global specialty pharmaceutical company focused on anti-infective treatments against serious and life-threatening infections. The contract strengthens SAJA's position in regional markets and supports Saudi Vision 2030 for nationalizing the pharmaceutical industry.
• Arab Maternal Fetal Medicine Expert GroupminorGTM or Marketing Partner · 1 January 2020SAJA sponsored the 'Pregnancy Management Challenges Webinar' in association with the Arab Maternal Fetal Medicine Expert Group, with attendance of more than 700 physicians from GCC countries and KSA. This partnership supports SAJA's OB-GYN product portfolio.
• NovartiscoreOEM/ Whitelabel/ Licensing Partner · 1 December 2015SAJA signed a licensing agreement with Novartis on 15 December 2015 to launch its first diabetes brand (Jalra and Jalra M) as a second brand for Novartis, using the active ingredient vildagliptin (Galvus). The contract also covers secondary packaging of some of Novartis's vital products at SAJA's manufacturing facility, reflecting confidence in SAJA's high-quality facilities.
• SanoficoreOEM/ Whitelabel/ Licensing Partner · 1 January 2015SAJA established a diabetes line in partnership with Sanofi in 2015, contributing to expanded diabetes treatment options in the MENA region. This partnership aligns with the high diabetes prevalence in Saudi Arabia (~20.6% of adults).
• Tamer GroupcoreStrategic or Co-development PartnerTamer Group is the premier Saudi healthcare company and majority shareholder in SAJA Pharmaceuticals. Established in 1922, Tamer Group is a leading supplier of healthcare products in the MENA region with annual turnover exceeding $1.3 billion. SAJA is the manufacturing arm of Tamer Group, producing the latest researched products as well as generics for the MENA region.
• Astellas Pharma Inc.coreStrategic or Co-development PartnerAstellas is a global pharmaceutical company with corporate origins in Japan. SAJA is a joint venture between Tamer Industries and Astellas Pharma Inc. Astellas engages in research, development, manufacture, import, and export of pharmaceutical products focusing on therapeutic fields including transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases.
• Daiichi Sankyo Company Ltd.coreStrategic or Co-development PartnerDaiichi Sankyo is a global pharmaceutical company with corporate origins in Japan, present in more than 20 countries with over 100 years of scientific expertise. SAJA is a joint venture between Tamer Industries and Daiichi Sankyo Company Ltd. The partnership provides innovative products and technology transfer for the MENA market.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Cipla: India-headquartered global pharmaceutical company with a significant MENA and emerging-markets presence across respiratory, cardiovascular, and oncology. Competes with SAJA on branded generics and licensing-in arrangements across the GCC and broader region.
• Dr. Reddy's Laboratories: India-headquartered global generics manufacturer with active MENA commercial operations, including partnerships for branded generics and biosimilars. Comparable as a global generics player expanding in the same MENA markets where SAJA operates.
• Hikma Pharmaceuticals: MENA-origin global specialty pharmaceutical company headquartered in Jordan, producing branded and injectable generics across MENA, US, and Europe. Broader and larger incumbent than SAJA, with overlapping MENA presence and direct competition in cardiovascular, anti-infectives, and oncology generics.

Others

• Astellas Pharma Inc. Japan-based global pharmaceutical company and JV shareholder of SAJA. Relevant as a key strategic partner and licensor of SAJA's urology and specialty products, shaping SAJA's product portfolio direction.
• Sanofi: Global pharmaceutical major and SAJA's diabetes-line licensing partner (since 2015) for vildagliptin-based products in MENA. Comparable as a multinational pharma company that partners with SAJA for regional commercialization rather than competing directly in the same channel.

Direct peers

• Gulf Pharmaceutical Industries (Julphar): UAE-based pharmaceutical manufacturer with MENA distribution, producing branded generics in diabetes, cardiovascular, and primary care categories. Directly comparable to SAJA as a Gulf-region pharma manufacturer with similar therapeutic breadth and regional MENA commercial reach.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi Arabia's largest pharmaceutical manufacturer, listed on Tadawul, producing branded generics across similar therapeutic categories (cardiovascular, diabetes, urology, antibiotics) with direct sales across MENA. Closest direct competitor to SAJA in the Saudi branded-generics space with overlapping product portfolios.
• Egyptian International Pharmaceutical Industries Company (EIPICO): One of Egypt's largest pharmaceutical manufacturers, producing branded generics across antibiotics, cardiovascular, and diabetes, with exports across MENA and Africa. Comparable to SAJA's Egyptian subsidiary footprint and overlapping regional export markets.
• Tabuk Pharmaceuticals Manufacturing Company: Saudi pharma manufacturer headquartered in Tabuk with a diversified branded-generics portfolio spanning cardiovascular, anti-infectives, CNS, and urology. Competes directly with SAJA for tenders and private-market share in KSA and exports to MENA.
• Avalon Pharma: Saudi Arabia-based pharmaceutical company focused on branded generics in dermatology, pain management, and primary care. Competes with SAJA in the Saudi branded-generics space and shares similar KSA distribution channels and HCP promotional model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubevimeo.com/753735963
• Xx.com/SAJA_Pharma
• LinkedInlinkedin.com/company/saudi-arabian-japanese-pharmaceutical-company-limited

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SAJA Pharmaceuticals